- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05024175
Dlouhodobé sledování subjektů léčených CARv3-TEAM-ET T buňkami
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
Přehled studie
Postavení
Podmínky
Detailní popis
This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.
No investigational treatment will be administered in this study.
The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.
Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).
Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Matthew J Frigault, MD
- Telefonní číslo: 617-643-6175
- E-mail: mfrigault@mgb.org
Studijní místa
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Nábor
- Massachusetts General Hospital
-
Vrchní vyšetřovatel:
- Matthew J Frigault, MD
-
Kontakt:
- Matthew J Frigault, MD
- Telefonní číslo: (617) 724-4000
- E-mail: mfrigault@mgb.org
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit
Popis
Inclusion Criteria:
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
Exclusion Criteria:
Subjects meeting the following criterion are to be excluded from study participation:
- Subject unable to comply with study requirements
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
CAR T cells
|
CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol Tumor Biopsy per protocol Blood Test per protocol |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival
Časové okno: 1 month
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
1 month
|
|
Overall Survival
Časové okno: 6 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
6 months
|
|
Overall Survival
Časové okno: 12 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
12 months
|
|
Overall Survival
Časové okno: 24 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
24 months
|
|
Progresison Free Survival
Časové okno: 1 month
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
1 month
|
|
Progresison Free Survival
Časové okno: 6 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
6 months
|
|
Progresison Free Survival
Časové okno: 12 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
12 months
|
|
Progresison Free Survival
Časové okno: 24 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
24 months
|
|
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
Časové okno: Up to 15 Years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
Up to 15 Years
|
|
New incidence of a hematologic disorder
Časové okno: up to 15 years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
up to 15 years
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
Časové okno: up to 15 years
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) |
up to 15 years
|
|
Vector-derived RCL
Časové okno: baseline and in 3 months, 6 months, and annually up to 15 years
|
Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA). |
baseline and in 3 months, 6 months, and annually up to 15 years
|
|
Assessment of CAR T cells persistence by VCN in peripheral blood
Časové okno: baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence |
baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
|
Progression-free Survival
Časové okno: From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
|
Overall Survival
Časové okno: From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
The time from post-CAR T cells infusion to the date of death. |
From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Matthew J Frigault, MD, Massachusetts General Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 20-721
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Časový rámec sdílení IPD
Data can be shared no earlier than 1 year following the date of publication
Kritéria přístupu pro sdílení IPD
Contact the Partners Innovations team at http://www.partners.org/innovation
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .